Circassia Group PLC
LSE:CIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Circassia Group PLC
Accounts Receivables
Circassia Group PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Circassia Group PLC
LSE:CIR
|
Accounts Receivables
£3.7m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accounts Receivables
£74m
|
CAGR 3-Years
39%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accounts Receivables
£96.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Accounts Receivables
£47.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
19%
|
|
|
Niox Group PLC
LSE:NIOX
|
Accounts Receivables
£4.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
4%
|
|
Circassia Group PLC
Glance View
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The firm operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements. The firm provides products and services in around 50 countries.
See Also
What is Circassia Group PLC's Accounts Receivables?
Accounts Receivables
3.7m
GBP
Based on the financial report for Dec 31, 2022, Circassia Group PLC's Accounts Receivables amounts to 3.7m GBP.
What is Circassia Group PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
0%
Over the last year, the Accounts Receivables growth was 42%. The average annual Accounts Receivables growth rates for Circassia Group PLC have been -33% over the past three years .
